-
Mashup Score: 3
The company missed first-quarter earnings forecasts by 4 cents a share, but beat sales expectations.
Source: www.investors.comCategories: General Medicine News, PayerTweet
-
Mashup Score: 5Teva Reports First Quarter 2024 Financial Results and Reaffirms 2024 Financial Outlook - 10 day(s) ago
Generics business and AUSTEDO ® growth lead Q1 2024 performance. Q1 2024 revenues of $3.8 billion reflect an increase of 5% in local currency terms, compared to Q1 2023. Generics business growth across all regions – increased by 9% in local currency terms globally, compared to Q1 2023. AUSTEDO – continued growth, up 67% (in the U.S.) from Q1 2023; reaffirming 2024 revenue outlook of ~$1.5 billion. AJOVY ® – revenues of $113 million in Q1 2024, up 18% from Q1 2023. Recent FDA approvals of SIML ANDI ® and
Source: www.tevausa.comCategories: General Medicine News, PayerTweet
-
Mashup Score: 5Teva Reports First Quarter 2024 Financial Results and Reaffirms 2024 Financial Outlook - 10 day(s) ago
Generics business and AUSTEDO ® growth lead Q1 2024 performance. Q1 2024 revenues of $3.8 billion reflect an increase of 5% in local currency terms, compared to Q1 2023. Generics business growth across all regions – increased by 9% in local currency terms globally, compared to Q1 2023. AUSTEDO – continued growth, up 67% (in the U.S.) from Q1 2023; reaffirming 2024 revenue outlook of ~$1.5 billion. AJOVY ® – revenues of $113 million in Q1 2024, up 18% from Q1 2023. Recent FDA approvals of SIML ANDI ® and
Source: www.tevausa.comCategories: General Medicine News, PayerTweet
-
Mashup Score: 0
The study met its primary endpoint achieving clinically meaningful and statistically significant reductions across all TEV-‘749 dose groups versus placebo in the Positive and Negative Syndrome Scale (PANSS) total score, a widely used assessment tool for schizophrenia symptom severity TEV-‘749 was well tolerated, with no incidence of post-injection delirium/sedation syndrome (PDSS) observed to date: additional safety data is being collected as part of the long-term follow-up SOLARIS study TEV-‘749 is being developed by Teva as a once-monthly subcutaneous long-acting injection of olanzapine with the use of SteadyTeq™ technology, a copolymer technology proprietary to Medincell Teva Pharmaceuticals, a U.S. affiliate of Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA), and Medincell (Euronext: MEDCL), today announced results from the efficacy portion of the Phase 3 Subcutaneous OLAnzapine extended-Release Injection Study (SOLARIS) trial evaluating TEV-‘749 in adult patients with
Source: ir.tevapharm.comCategories: General Medicine News, PayerTweet
-
Mashup Score: 9Alvotech and Teva Announce U.S. FDA Approval of SELARSDI™ (ustekinumab-aekn), biosimilar to Stelara® (ustekinumab) - 1 month(s) ago
SELARSDI is a pproved for both adult and pediatric indications and is the second biosimilar approved under the strategic partnership between Alvotech and Teva SELARSDI is expected to be marketed in the U.S. on or after February 21, 2025, following a settlement agreement with Johnson & Johnson, the manufacturer of Stelara SELARSDI was developed and is manufactured by Alvotech using murine cell (Sp2/0) and a continuous perfusion process, which are the same type of cells and process used for the production
Source: www.tevapharm.comCategories: General Medicine News, PayerTweet
-
Mashup Score: 1
Almost 80% of patients with Huntington’s disease (HD) chorea were able to ach ieve optimal dosing within four weeks with the 4-week Titration Kit in final START study results START study results further support real-world effectiveness, safety, adherence and patient satisfaction with the 4-week Titration Kit for AUSTEDO AUSTEDO remains the only vesicular monoamine transporter 2 (VMAT2) inhibitor available with 3-year data for this progressive condition 1,2 TEL AVIV, Israel & PARSIPPANY, N.J.–(BUSINESS
Source: www.tevausa.comCategories: General Medicine News, PayerTweet
-
Mashup Score: 5
PK modeling data provide insights into potential dosing conversions and strategies for switching to UZEDY from a long-acting injectable (LAI) formulation of risperidone microspher es (R064766) Additional UZEDY data include a new analysis from the Phase 3 RISE trial reinforcing its efficacy and safety profile in adults with schizophrenia ADVANCE, a global survey study, will also provide real-world findings on LAI utilization from healthcare professionals, caregivers and patients TEL AVIV, Israel & PARSIPPAN
Source: www.tevausa.comCategories: General Medicine News, PayerTweet
-
Mashup Score: 11Teva and mAbxience Announce Strategic Global Licensing Agreement for Oncology Biosimilar Candidate - 1 month(s) ago
Teva and mAbxience enter into a strategic global partnership for in-licensing of an oncology biosimilar candidate Agreement signals a major step in mAbxience’s global expansion strategy and advances a key element of Teva’s Pivot to Growth strategy to expand its biosimilar pipeline through business development Teva-mAbxience partnership reflects the companies’ shared commitment to expand access to critical healthcare solutions to more patients who need them Teva Pharmaceuticals International GmbH, a subsidiary of Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) and mAbxience, a Fresenius Kabi majority-owned group with partial ownership from Insud Pharma, today announced they have entered a strategic licensing agreement for a biosimilar candidate currently in development for the treatment of multiple oncology indications. Biosimilars show promising potential in providing more cost-effective alternatives to existing oncology therapies, thereby addressing a critical need in
Source: ir.tevapharm.comCategories: General Medicine News, PayerTweet
-
Mashup Score: 11
Collaboration combines Teva’s expertise in respiratory technology development and Launch Therapeutics’ innovative late-stage drug development model to progress Teva’s Dual-Action Asthma Rescue Inhaler (TEV-‘248) program Development funding agreement to provide up to $150 million to offset program costs and to accelerate clinical research for Teva’s TEV-‘248 program in line with Teva’s Pivot to Growth strategy to step up innovation and advance its innovative pipeline Teva’s TEV-‘248 has the potential to be the first Dual-Action Asthma Rescue Inhaler combining an Inhaled Corticosteroid with a Short-Acting Beta-Agonist (ICS-SABA) for both adult and pediatric asthma indications Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) and Launch Therapeutics, Inc., today announced a clinical collaboration agreement to further accelerate the clinical research program of Teva’s ICS-SABA (TEV-‘248). Teva and Abingworth, a leading international life sciences investment group, part of global
Source: ir.tevapharm.comCategories: General Medicine News, PayerTweet-
Today Teva announced a clinical collaboration agreement with Launch Therapeutics and a strategic funding development agreement with @Abingworthbio to accelerate development of our dual-action asthma rescue inhaler respiratory program. Read more: https://t.co/0KqB2lyypD #Asthma https://t.co/ZdDurPB4dt
-
-
Mashup Score: 12
SIMLANDI is the first citrate-free, high-concentration biosimilar to be designated interchangeable to Humira in the U.S. SIMLANDI is the first biosimilar approval under the strategic partnership between Alvotech and Teva in the U.S. market SIMLANDI will qualify for interchangeable exclusivity in the U.S. for some concentration strengths Alvotech (NASDAQ: ALVO) and Teva Pharmaceuticals, a U.S. affiliate of Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA), today announced that the U.S. Food and Drug Administration (FDA) has approved SIMLANDI (adalimumab-ryvk) injection, as an interchangeable biosimilar to Humira, for the treatment of adult rheumatoid arthritis, juvenile idiopathic arthritis, adult psoriatic arthritis, adult ankylosing spondylitis, Crohn’s disease, adult ulcerative colitis, adult plaque psoriasis, adult hidradenitis suppurativa and adult uveitis. In 2023, Humira was one of the highest grossing pharmaceutical products in the world, with sales in the U.S. of
Source: ir.tevapharm.comCategories: General Medicine News, PayerTweet
RT @IBDinvestors: Teva Pharma Shoots To 5-Year High With Good News For Its Blockbuster Hopeful https://t.co/udxmerqMza